Circulating regulatory anti–T cell receptor antibodies in patients with myasthenia gravis
J. Clin. Invest. Florence Jambou, et al. 112:265 doi:10.1172/JCI16039 [Go to this article.]

Figure 1
Serum IgG Ab’s against TCR peptides in controls and EOMG patients with or without HLA-DR3 determined by ELISA. Titrations were carried out with serial dilutions of serum from 1:10 to 1:5,000. Sample dilutions were run in duplicate for each individual. The titer was the reciprocal of the dilution giving an OD of 0.2 in the linear portion of the curve in the inset in (a), where representative titers were 90, 120, and 700 for a healthy control, an HLA-DR3^– MG patient, and an HLA-DR3⁺ MG patient, respectively. (a) We tested sera from MG patients who had not undergone prior TCR vaccination (n = 40), age-matched healthy controls (n = 14), and patients with other clearly defined autoantibodies (n = 46). The horizontal line corresponds to the mean titer of healthy controls + 2.6 SD. To compare with the EOMG patients, we used the Mann-Whitney test. (b) Anti-Vβ5.1 Ab titers in EOMG patients with or without HLA-DR3. Serum titers of Ab’s against CDR2 peptides from Vβ6.7 (c) or Vβ14 (d) in HLA-DR3⁺ EOMG patients (n = 10), HLA-DR3^– EOMG patients (n = 5), and healthy controls (n = 6). The P values indicated in b–d were calculated versus the HLA-DR3⁺ MG patient group. Each point corresponds to an individual patient. Horizontal bars indicate the mean.